Benzinga | Apr 20, 2021 06:41AM EDT

Illumina Says Disagrees With European Commission's Directorate-General For Competition's Decision To Review Co.'s Acquisition Of GRAIL

Illumina, Inc. (NASDAQ:ILMN), today announced that it disagrees with the European Commission's Directorate-General for Competition's decision to review Illumina's acquisition of GRAIL, a company founded to accelerate early screening of cancer. Illumina will continue to work with the Directorate-General to bring the investigation to conclusion. Illumina remains committed to the transaction, the impact of which would accelerate the adoption of a multi-cancer early detection blood test.